Cargando…

Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor, Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial Growth Factor Levels, and the Systemic Symptoms like Capillary Leak Syndrome

Several problems such as myalgia, arthralgia, fever, dyspnea, generalized edema, and pleural effusion can occur in cancer patients following the chemotherapy, especially at the first cycle of the first chemotherapy treatment. Although it is assumed that some cytokines are associated with the develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Keskin, Havva, Cadirci, Kenan, Demirkazik, Ahmet, Akbulut, Hakan, Yalcin, Bulent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558530/
https://www.ncbi.nlm.nih.gov/pubmed/31217693
http://dx.doi.org/10.1177/1179299X19854447
_version_ 1783425645381943296
author Keskin, Havva
Cadirci, Kenan
Demirkazik, Ahmet
Akbulut, Hakan
Yalcin, Bulent
author_facet Keskin, Havva
Cadirci, Kenan
Demirkazik, Ahmet
Akbulut, Hakan
Yalcin, Bulent
author_sort Keskin, Havva
collection PubMed
description Several problems such as myalgia, arthralgia, fever, dyspnea, generalized edema, and pleural effusion can occur in cancer patients following the chemotherapy, especially at the first cycle of the first chemotherapy treatment. Although it is assumed that some cytokines are associated with the development of these symptoms and signs, their pathophysiology has not been discovered completely yet. They are usually mild, but they may rarely progress to the severe stage of “Systemic Capillary Leak Syndrome” with a high mortality rate. The objective of this study was to investigate the association between the serum levels of interleukin-2 (IL-2), interleukin-11 (IL-11), tumor necrosis factor alpha (TNF-α), vascular endothelial growth factor (VEGF), and these symptoms and signs. A total of 44 cancer patients who had neither heart, lung, liver, renal, or thyroid disease were recruited into this study. Their symptoms and signs were examined and questioned before the first cycle of the first chemotherapy treatment and the 24 h after this chemotherapy. All participant’s serum samples were taken, and the VEGF, TNF, IL-2, and IL-11 levels were studied. There was no association between the chemotherapeutic drugs, and the symptoms and signs such as edema, dyspnea, coughing, and flu-like symptoms. There was a significant decrease in IL-11 levels in the other treatment group compared with the group receiving paclitaxel, docetaxel, gemcitabine, and vinorelbine in the first day following chemotherapy (P = .006). However, no relation was observed between the symptoms and signs, the response to the chemotherapy, and the serum levels of VEGF, TNF, IL-2, and IL-11. These symptoms and life-threatening syndrome have been a current topic between the clinicians. Although some drugs and mediators are accused, its pathophysiology has not been discovered completely yet. In this study, we could not detect any association between the symptoms, signs, and the cytokine levels following the chemotherapy.
format Online
Article
Text
id pubmed-6558530
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-65585302019-06-19 Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor, Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial Growth Factor Levels, and the Systemic Symptoms like Capillary Leak Syndrome Keskin, Havva Cadirci, Kenan Demirkazik, Ahmet Akbulut, Hakan Yalcin, Bulent Biomark Cancer Original Research Several problems such as myalgia, arthralgia, fever, dyspnea, generalized edema, and pleural effusion can occur in cancer patients following the chemotherapy, especially at the first cycle of the first chemotherapy treatment. Although it is assumed that some cytokines are associated with the development of these symptoms and signs, their pathophysiology has not been discovered completely yet. They are usually mild, but they may rarely progress to the severe stage of “Systemic Capillary Leak Syndrome” with a high mortality rate. The objective of this study was to investigate the association between the serum levels of interleukin-2 (IL-2), interleukin-11 (IL-11), tumor necrosis factor alpha (TNF-α), vascular endothelial growth factor (VEGF), and these symptoms and signs. A total of 44 cancer patients who had neither heart, lung, liver, renal, or thyroid disease were recruited into this study. Their symptoms and signs were examined and questioned before the first cycle of the first chemotherapy treatment and the 24 h after this chemotherapy. All participant’s serum samples were taken, and the VEGF, TNF, IL-2, and IL-11 levels were studied. There was no association between the chemotherapeutic drugs, and the symptoms and signs such as edema, dyspnea, coughing, and flu-like symptoms. There was a significant decrease in IL-11 levels in the other treatment group compared with the group receiving paclitaxel, docetaxel, gemcitabine, and vinorelbine in the first day following chemotherapy (P = .006). However, no relation was observed between the symptoms and signs, the response to the chemotherapy, and the serum levels of VEGF, TNF, IL-2, and IL-11. These symptoms and life-threatening syndrome have been a current topic between the clinicians. Although some drugs and mediators are accused, its pathophysiology has not been discovered completely yet. In this study, we could not detect any association between the symptoms, signs, and the cytokine levels following the chemotherapy. SAGE Publications 2019-06-10 /pmc/articles/PMC6558530/ /pubmed/31217693 http://dx.doi.org/10.1177/1179299X19854447 Text en © The Author(s) 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Keskin, Havva
Cadirci, Kenan
Demirkazik, Ahmet
Akbulut, Hakan
Yalcin, Bulent
Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor, Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial Growth Factor Levels, and the Systemic Symptoms like Capillary Leak Syndrome
title Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor, Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial Growth Factor Levels, and the Systemic Symptoms like Capillary Leak Syndrome
title_full Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor, Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial Growth Factor Levels, and the Systemic Symptoms like Capillary Leak Syndrome
title_fullStr Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor, Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial Growth Factor Levels, and the Systemic Symptoms like Capillary Leak Syndrome
title_full_unstemmed Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor, Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial Growth Factor Levels, and the Systemic Symptoms like Capillary Leak Syndrome
title_short Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor, Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial Growth Factor Levels, and the Systemic Symptoms like Capillary Leak Syndrome
title_sort following chemotherapy: serum cytokine (tumor necrosis factor, interleukin-2, interleukin-11), immunoglobulin, complement, vascular endothelial growth factor levels, and the systemic symptoms like capillary leak syndrome
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558530/
https://www.ncbi.nlm.nih.gov/pubmed/31217693
http://dx.doi.org/10.1177/1179299X19854447
work_keys_str_mv AT keskinhavva followingchemotherapyserumcytokinetumornecrosisfactorinterleukin2interleukin11immunoglobulincomplementvascularendothelialgrowthfactorlevelsandthesystemicsymptomslikecapillaryleaksyndrome
AT cadircikenan followingchemotherapyserumcytokinetumornecrosisfactorinterleukin2interleukin11immunoglobulincomplementvascularendothelialgrowthfactorlevelsandthesystemicsymptomslikecapillaryleaksyndrome
AT demirkazikahmet followingchemotherapyserumcytokinetumornecrosisfactorinterleukin2interleukin11immunoglobulincomplementvascularendothelialgrowthfactorlevelsandthesystemicsymptomslikecapillaryleaksyndrome
AT akbuluthakan followingchemotherapyserumcytokinetumornecrosisfactorinterleukin2interleukin11immunoglobulincomplementvascularendothelialgrowthfactorlevelsandthesystemicsymptomslikecapillaryleaksyndrome
AT yalcinbulent followingchemotherapyserumcytokinetumornecrosisfactorinterleukin2interleukin11immunoglobulincomplementvascularendothelialgrowthfactorlevelsandthesystemicsymptomslikecapillaryleaksyndrome